At Horizons in Advanced Practice, Evangelia Nezis, NP, shares early results with oral peptides and takeaways on type 2 ...

Mark Lebwohl, MD, discusses atopic march data and systemic treatment options for pediatric atopic dermatitis. Mark Lebwohl, ...

A melanoma expert discusses gaps in dermoscopy education, cognitive bias during skin examinations, and strategies to improve ...

C, shares how journal case reports led to rapid results for a patient with an uncommon skin condition. After nearly 10 years on isotretinoin with minimal improvement, Sharon Doering, PA-C, tried a ...

At Horizons in Advanced Practice, Douglas DiRuggiero, DMSc, MHS, PA-C, reviewed oral and targeted psoriasis therapies and ...

Updated SKYRIZI labeling allows clinicians to use clinical judgment when determining the need for TB evaluation before treatment.

Aclaris Therapeutics announced positive phase 1b proof-of-concept results for ATI-052, an investigational bispecific antibody ...

Patients on Medicare often do everything insurers ask, including trying and failing the standard topicals, and still can’t ...

The FDA has accepted Lynch Regenerative Medicine’s (LRM) investigational new drug (IND) application for a phase 2b clinical ...

Oral JAK inhibitors are preferred first-line long-term therapy for severe adult AA; FDA-approved agents are favored, whereas dupilumab is an alternative for patients with comorbid atopy. Experts ...

In "Transitioning From Self-Injection to HCP-Administered Psoriasis Therapy," our experts examine what to do when a patient ...

One of the most common misconceptions Feldman encounters among patients and caregivers is that eczema is simply a problem of ...